GB1107

Research use only, not for human use.

GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3).

GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3); displays >100-fold lower affinity for most of the tested human galectins, and 20 and 4-fold lower affinity for galectin-2 and the C-terminal CRD of galectin-4, respectively; prevents human lung adenocarcinoma growth in vivo, increases tumor M1 macrophage polarization and CD8+ T cell infiltration; GB1107 also can potentiate the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules.

——

Animal Model:CD-1 nude female mice received 3x106 human lung adenocarcinoma cells (A549).Dosage:10 mg/kg Administration:Oral once daily from day 18-30 post implantation.Result:Resulted in significantly reduced tumor growth and final tumor weights.

GB-1107 | GB 1107

Cytoskeleton/Cell Adhesion Molecules

Galectin

Galectin

——

——

1978336-61-6

522.32

C20H16Cl2F3N3O4S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (95.73 mM)

O[C@H]([C@@H](N1N=NC(C2=CC(F)=C(F)C(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@H]3SC4=CC=C(Cl)C(Cl)=C4

3,4-dichlorophenyl 3-deoxy-3-[4(3,4,5-trifluorophenyl)-1H-1,2,3- triazol-1-yl]-1-thio-α-D-galactopyranoside

(-20℃)

With Ice Pack

≥ 2 years